Fine Structure Ventures Research
Investment Thesis
Fine Structure Ventures (FSV) is an early-stage venture fund built to back "disruptive scientific and technological innovation," taking companies from lab-scale proof of concept to global commercial scale. The firm applies what it calls a first-principles approach: it looks for technologies that, if realized at scale, would have an obvious, dramatic, global impact, and it aims for unprecedented rigor in evaluating scientific claims before committing capital, explicitly drawing an analogy to the precision standards of quantum physics (the fine structure constant is the firm's namesake). FSV partners closely with "scientist-entrepreneurs" translating deep technical breakthroughs out of academic and national labs into venture-scale businesses, and the firm says it is rooted in over 50 years of collective investing experience across its team and advisory relationship.
Sector Focus
FSV invests across five core deep-tech verticals: energy and electrification, aerospace and defense, next-generation computing, materials and manufacturing, and biology. In practice this spans nuclear and geothermal energy (Aalo Atomics, Quaise Energy, Commonwealth Fusion Systems), grid and power electronics (DG Matrix, VEIR, Feon), advanced materials and critical-metals processing (pH7 Technologies, Boston Metal, Nitricity, Osmoses, Sepion Technologies, Caelux, Ambient Photonics, Pallidus), next-gen computing and semiconductors (FemtoAI, Finwave, iPronics, BoolSi), aerospace launch and space infrastructure (Gilmour Space Technologies, Radian Aerospace, Hedron), and synthetic biology / biomanufacturing (Constructive Bio, Debut Biotech, Hoxton Farms, Nulixir, Phytoform).
Stage Focus
FSV is an early-stage investor, concentrated at pre-seed, seed, and Series A, with the ability to follow on through later rounds (the firm's site describes support "from pre-seed to pre-IPO"). Board representation is high: FSV reports sitting on the board of more than 80% of its portfolio companies, consistent with a lead/co-lead early-stage posture rather than a passive check-writer.
Check Size
Exact check-size ranges are not publicly disclosed. Deal data shows the firm participating in rounds averaging in the tens of millions at Series A and smaller (~$5-30M) rounds at seed, consistent with meaningful early ownership stakes rather than small syndicate tickets.
Lead Tendency
FSV both leads and follows. It led pH7 Technologies' $25.6M Series B (announced December 2025) and BoolSi's $6M seed (announced 2026), while participating as one of several investors in Engine Ventures-led $60M Series A for DG Matrix (February 2026).
Recent Activity
FSV has been active through 2025 and 2026: leading pH7 Technologies' Series B in December 2025, participating in DG Matrix's $60M Series A in February 2026, and leading BoolSi's $6M seed round in mid-2026. Portfolio company Commonwealth Fusion Systems raised $1B in July 2026 (bringing its total capital to roughly $4B) to build its first commercial fusion power plant, underscoring FSV's exposure to capital-intensive, long-horizon energy bets.
Portfolio Highlights
FSV's portfolio spans two named funds (Fund I and Fund II) and includes 300+ active patents across portfolio companies and $2B+ of collective capital raised. Notable names include Commonwealth Fusion Systems (fusion energy), Boston Metal (green steel), Mainspring Energy (linear generators), Quaise Energy (geothermal drilling), Gilmour Space Technologies and Radian Aerospace (launch vehicles), and Aalo Atomics (microreactors). Exits to date include Mantle (precision metal 3D printing) and Hedron (space infrastructure).
Team
- Amrit Jalan, PhD — Principal. Identifies high-potential technologies and partners with leadership teams to scale them; previously Director at Eni Next and held technology/strategy roles at ExxonMobil. MBA, Harvard Business School; MS/PhD Chemical Engineering, MIT; BS Chemical Engineering, IIT Bombay. Focus includes Caelux and Osmoses.
- Shyam Kamadolli — Managing Director. Previously led early-stage venture investments at F-Prime Capital.
- Jennifer Uhrig — Senior Managing Director.
- Dionis Minev, PhD — Associate. Focuses on biology, aerospace, and computing; formerly Senior Scientist at an early-stage DNA data storage startup and Staff Scientist on Harvard Wyss Institute's Molecular Robotics Platform. PhD Engineering Sciences, Harvard; postdoc with William Shih at Wyss/Dana-Farber.
- Tobias Egle, PhD — Senior Associate.
- David Needell, PhD — Senior Associate.
- Crissy Derome — Project Coordinator. Manages executive operations and cross-functional initiatives for the FSV team; prior senior administrative roles at Fidelity Investments and Devonshire Investors.
Decision Process
FSV operates as a partnership-style investment team advised by F-Prime Capital (as of July 1, 2024, F-Prime Capital advises Fine Structure Ventures, with Impresa Management LLC providing underlying advisory/management services). This is not a solo-GP structure; investment decisions run through the FSV investment team.
Founder Preferences
FSV backs "scientist-entrepreneurs": technical founders, often with PhD-level domain expertise, who are commercializing genuine scientific or engineering breakthroughs rather than applying existing technology to a new market. The team's own composition (multiple PhDs across chemical engineering, materials, and biology) signals a preference for deeply technical counterparties who can defend the underlying science.
Geographic Focus
Headquartered in Cambridge, MA, with a portfolio spanning the US, Australia (Gilmour Space Technologies), and other geographies; the firm states it backs companies "leveraging scientific breakthroughs all over the world," though the bulk of visible portfolio activity is US-based.